Innate lymphoid cells are activated in HFRS, and their function can be modulated by hantavirus-induced type I interferons

PLoS Pathog. 2024 Jul 22;20(7):e1012390. doi: 10.1371/journal.ppat.1012390. eCollection 2024 Jul.

Abstract

Hantaviruses cause the acute zoonotic diseases hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Infected patients show strong systemic inflammation and immune cell activation. NK cells are highly activated in HFRS, suggesting that also other innate lymphoid cells (ILCs) might be responding to infection. Here, we characterized peripheral ILC responses, and measured plasma levels of soluble factors and plasma viral load, in 17 Puumala virus (PUUV)-infected HFRS patients. This revealed an increased frequency of ILC2 in patients, in particular the ILC2 lineage-committed c-Kitlo ILC2 subset. Patients' ILCs showed an activated profile with increased proliferation and displayed altered expression of several homing markers. How ILCs are activated during viral infection is largely unknown. When analyzing PUUV-mediated activation of ILCs in vitro we observed that this was dependent on type I interferons, suggesting a role for type I interferons-produced in response to virus infection-in the activation of ILCs. Further, stimulation of naïve ILC2s with IFN-β affected ILC2 cytokine responses in vitro, causing decreased IL-5 and IL-13, and increased IL-10, CXCL10, and GM-CSF secretion. These results show that ILCs are activated in HFRS patients and suggest that the classical antiviral type I IFNs are involved in shaping ILC functions.

MeSH terms

  • Adult
  • Cytokines / immunology
  • Cytokines / metabolism
  • Female
  • Hemorrhagic Fever with Renal Syndrome* / immunology
  • Hemorrhagic Fever with Renal Syndrome* / virology
  • Humans
  • Immunity, Innate* / immunology
  • Interferon Type I* / immunology
  • Interferon Type I* / metabolism
  • Lymphocytes* / immunology
  • Lymphocytes* / metabolism
  • Male
  • Middle Aged
  • Orthohantavirus / immunology
  • Puumala virus / immunology

Substances

  • Interferon Type I
  • Cytokines

Grants and funding

This study was supported by grants from the Swedish Research Council (project 2018-02646 to JK), Karolinska Institutet Research Foundation (project 2020-01469 to MG), The Center for Medical Innovation (CIMED) (project 2020-0141 to JK), the Academy of Finland (project 321809 to TS), Magnus Ehrnrooth Foundation (to AV), and Sigrid Jusélius Foundation (to AV and JuM), and the Competitive State Research Financing of the Responsibility Area of Tampere University Hospital (9AA050 and 9AB046 to JuM and 9AA052 to SM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.